MedPath

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

Phase 3
Completed
Conditions
Advanced Stage Parkinson's Disease
Interventions
Drug: Levodopa (Pardoprunox)
Drug: Placebo Comparator
Registration Number
NCT00406588
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
295
Inclusion Criteria
  • Diagnosis of idiopathic Parkinson's Disease,
  • advance stage of disease,
  • Modified Hoehn & Yahr stage II-IV,
  • presence of a recognizable 'on' and 'off' state (motor fluctuations) and stable treatment with levodopa for at least 28 days prior to randomization
Read More
Exclusion Criteria
  • 'on-off' phenomena or 'yo-yoing' and/or an abrupt unpredictable loss of efficacy unrelated to the timing of L-DOPA administration,
  • Prevalent expression of troublesome dyskinesias during 'on' time at waking hours,
  • Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists,
  • Previous surgery for the treatment of PD
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Levodopa (Pardoprunox)-
2Placebo Comparator-
Primary Outcome Measures
NameTimeMethod
Change from baseline to end of the maintenance period or at the early termination visit in 'off'-time as recorded in patients' home diaries.12 weeks
Secondary Outcome Measures
NameTimeMethod
Increase of 'on'-time, change from baseline in the total score of the UPDRS part 2+3, and PDQ-3912 weeks

Trial Locations

Locations (87)

Site 220

πŸ‡ΊπŸ‡Έ

LaJolla, California, United States

Site 223

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

Site 211

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

Site 214

πŸ‡ΊπŸ‡Έ

Fort Lauderdale, Florida, United States

Site 218

πŸ‡ΊπŸ‡Έ

Gainsville, Florida, United States

Site 213

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

Site 212

πŸ‡ΊπŸ‡Έ

East Lansing, Michigan, United States

Site 219

πŸ‡ΊπŸ‡Έ

Augusta, Georgia, United States

Site 221

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Site 224

πŸ‡ΊπŸ‡Έ

Lexington, Kentucky, United States

Site 216

πŸ‡ΊπŸ‡Έ

Kansas City, Kansas, United States

Site 217

πŸ‡ΊπŸ‡Έ

St. Louis, Missouri, United States

Site 222

πŸ‡ΊπŸ‡Έ

Durham, North Carolina, United States

Site 210

πŸ‡ΊπŸ‡Έ

Toledo, Ohio, United States

Site 215

πŸ‡ΊπŸ‡Έ

Houston, Texas, United States

Site 103

πŸ‡¦πŸ‡·

Buenos Aires, Argentina

Site 102

πŸ‡¦πŸ‡·

Buenos Aires, Argentina

Site 101

πŸ‡¦πŸ‡·

Buenos Aires, Argentina

Site 100

πŸ‡¦πŸ‡·

Buenos Aires, Argentina

Site 107

πŸ‡¦πŸ‡·

Buenos Aires, Argentina

Site 106

πŸ‡¦πŸ‡·

Buenos Aires, Argentina

Site 109

πŸ‡¦πŸ‡·

Buenos Aires, Argentina

Site 104

πŸ‡¦πŸ‡·

Mar del Plata, Argentina

Site 105

πŸ‡¦πŸ‡·

Cordoba, Argentina

Site 108

πŸ‡¦πŸ‡·

Santa Fe, Argentina

Site 114

πŸ‡§πŸ‡·

Alto da Gloria, Brazil

Site 113

πŸ‡§πŸ‡·

Belo Horizonte, Brazil

Site 112

πŸ‡§πŸ‡·

Campinas, Brazil

Site 116

πŸ‡§πŸ‡·

Marilia, Brazil

Site 111

πŸ‡§πŸ‡·

Porto Alegre, Brazil

Site 117

πŸ‡§πŸ‡·

Ribeirao Preto, Brazil

Site 118

πŸ‡§πŸ‡·

Porto Alegre, Brazil

Site 119

πŸ‡§πŸ‡·

Salvador, Brazil

Site 115

πŸ‡§πŸ‡·

Sao Paulo, Brazil

Site 110

πŸ‡§πŸ‡·

Sao Paulo, Brazil

Site 125

πŸ‡§πŸ‡·

Sao Paulo, Brazil

Site 123

πŸ‡§πŸ‡¬

Plovdiv, Bulgaria

Site 120

πŸ‡§πŸ‡¬

Sofia, Bulgaria

Site 121

πŸ‡§πŸ‡¬

Sofia, Bulgaria

Site 122

πŸ‡§πŸ‡¬

Sofia, Bulgaria

Site 133

πŸ‡¨πŸ‡¦

Halifax, Canada

Site 124

πŸ‡§πŸ‡¬

Sofia, Bulgaria

Site 136

πŸ‡¨πŸ‡¦

Calgary, Canada

Site 137

πŸ‡¨πŸ‡¦

Greenfield Park, Canada

Site 132

πŸ‡¨πŸ‡¦

Markham, Canada

Site 134

πŸ‡¨πŸ‡¦

Ottawa, Canada

Site 139

πŸ‡¨πŸ‡¦

Toronto, Canada

Site 138

πŸ‡¨πŸ‡¦

Peterborough, Canada

Site 130

πŸ‡¨πŸ‡¦

Montreal, Canada

Site 135

πŸ‡¨πŸ‡¦

Sainte-Anne, Canada

Site 140

πŸ‡¨πŸ‡±

Santiago de Chile, Chile

Site 131

πŸ‡¨πŸ‡¦

Windsor, Canada

Site 141

πŸ‡¨πŸ‡±

Santiago de Chile, Chile

Site 143

πŸ‡¨πŸ‡±

Santiago de Chile, Chile

Site 151

πŸ‡¨πŸ‡΄

Bogota, Colombia

Site 154

πŸ‡¨πŸ‡΄

Bogota, Colombia

Site 152

πŸ‡¨πŸ‡΄

Bogota, Colombia

Site 150

πŸ‡¨πŸ‡΄

Medellin, Colombia

Site 184

πŸ‡΅πŸ‡ͺ

Bellavista Callao, Peru

Site 193

πŸ‡·πŸ‡Ί

Kazan, Russian Federation

Site 190

πŸ‡·πŸ‡Ί

Moscow, Russian Federation

Site 194

πŸ‡·πŸ‡Ί

Moscow, Russian Federation

Site 191

πŸ‡·πŸ‡Ί

Saint-Petersburg, Russian Federation

Site 197

πŸ‡·πŸ‡Ί

Moscow, Russian Federation

Site 198

πŸ‡·πŸ‡Ί

Saint Petersburg, Russian Federation

Site 192

πŸ‡·πŸ‡Ί

Saint-Petersburg, Russian Federation

Site 204

πŸ‡ΊπŸ‡¦

Dnepropetrovsk, Ukraine

Site 195

πŸ‡·πŸ‡Ί

Saint-Petersburg, Russian Federation

Site 196

πŸ‡·πŸ‡Ί

Yaroslavl, Russian Federation

Site 206

πŸ‡ΊπŸ‡¦

Kharkiv, Ukraine

Site 202

πŸ‡ΊπŸ‡¦

Kyiv, Ukraine

Site 205

πŸ‡ΊπŸ‡¦

Lviv, Ukraine

Site 208

πŸ‡ΊπŸ‡¦

Simferopol, Ukraine

Site 172

πŸ‡±πŸ‡Ή

Kaunas, Lithuania

Site 170

πŸ‡±πŸ‡Ή

Vilnius, Lithuania

Site 171

πŸ‡±πŸ‡Ή

Vilnius, Lithuania

Site 180

πŸ‡΅πŸ‡ͺ

Lima, Peru

Site 181

πŸ‡΅πŸ‡ͺ

Lima, Peru

Site 182

πŸ‡΅πŸ‡ͺ

Lima, Peru

Site 183

πŸ‡΅πŸ‡ͺ

Lima, Peru

Site 207

πŸ‡ΊπŸ‡¦

Zaporizhya, Ukraine

Site 153

πŸ‡¨πŸ‡΄

Bogota, Colombia

Site 142

πŸ‡¨πŸ‡±

Valdivia, Chile

Site 201

πŸ‡ΊπŸ‡¦

Kyiv, Ukraine

Site 203

πŸ‡ΊπŸ‡¦

Poltava, Ukraine

Site 200

πŸ‡ΊπŸ‡¦

Vinnitsa, Ukraine

Site 160

πŸ‡±πŸ‡»

Riga, Latvia

Β© Copyright 2025. All Rights Reserved by MedPath